Cardiac Dimensions, Inc.
5540 Lake Washington Boulevard NE
40 articles with Cardiac Dimensions, Inc.
REDUCE FMR Study Shows Cardiac Dimensions' Carillon® System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure
Published in peer-reviewed Journal of the American College of Cardiology: Heart Failure
Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation
Cardiac Dimensions® announced the Carillon Mitral Contour System® has been implanted in 1,000 patients in the United States, Europe, Australia, Turkey and the Middle East.
New Data Confirms Cardiac Dimensions' Carillon® System Provides Acute Hemodynamic Efficacy In Patients With Functional Mitral Regurgitation
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments to address functional mitral regurgitation in patients with heart failure, presented new data confirming significant reduction in regurgitant volume directly after implantation of the Carillon Mitral Contour System® at the German Society of Cardiology annual congress, DGK 2019.
Medical Device Industry Expert to Spearhead European Sales of the Carillon Mitral Contour System
With Reimbursement in Place and Positive Late-Breaking Data, Company Expects Continued Growth in Germany
Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment
In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume
Cardiac Dimensions Announces Late-Breaking Data to be Presented at The Transcatheter Cardiovascular Therapeutics Conference (TCT) 2018
Cardiac Dimensions today announced that key data from the company’s REDUCE FMR Trial will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference
Cardiac Dimensions Announces the Randomization of its First Patient in the U.S. Pivotal Trial – The CARILLON Trial
Multi-Center Study to Evaluate Innovative Minimally Invasive Treatment for Functional Mitral Regurgitation
Cardiac Dimensions Announces $39 Million Series B Financing for Innovative Device to Treat Patients With Heart Failure
Funds to be Used for Clinical Studies and Commercial Expansion in the European Union and Australia
Cardiac Dimensions Announces Investigational Device Exemption Approval From FDA To Conduct U.S. Pivotal Study Of The Carillon Mitral Contour System For Functional Mitral Regurgitation
Cardiac Dimensions Release: Carillon Mitral Contour System Associated With Significant Improvement Of Functional Mitral Regurgitation
Cardiac Dimensions, Inc. Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System
Cardiac Dimensions, Inc. Initiates European Commercialization of CARILLON® Mitral Contour System®